Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Hualing Pharmaceutical's second-generation GKA launches phase 1 clinical trial in the US and completes the enrollment of the first patient
Glonghui, April 26 | Hualing Pharmaceutical (2552.HK) announced that the first phase clinical trial of a second-generation glucokinase activator (second-generation GKA) has officially started in the US, and the first case was enrolled on April 25, local time in the US. The trial was a randomized, double-blind, placebo-controlled, single-dose escalation pharmacokinetics and pharmacodynamics study in 40 US patients with type 2 diabetes (T2D). The second-generation GKA is a new molecular entity with optimized physico-chemical properties. Using Hualing Pharmaceutical's proprietary formulation technology, it is designed for oral administration once a day. Second generation GKA
華領醫藥-B:年報 2023
Changes in Hong Kong stocks | Hualing Pharmaceutical-B (02552.HK) rose more than 12%, the company had plenty of cash in hand, and second-generation GKA's clinical practice progressed smoothly in the US
Hualing Pharmaceutical-B (02552.HK) rose by more than 12%. As of press release, it rose 12.24% to HK$1.65, with a turnover of HK$2.11,400.
Hualing Pharmaceutical (02552) announces 2023 results: R&D expenses of about 172 million yuan to actively promote the overseas market layout of second-generation GKA
On March 28, Hualing Pharmaceutical (02552) announced its 2023 results
Hualing Pharmaceutical: Second-generation GKA is being promoted to Phase I research in the US. Sales of doglitin are expected to increase
Glonghui, March 28 | Hualing Pharmaceutical announced its 2023 results. The company's first commercial product, dogliestine, was successfully included in the national medical insurance drug catalogue. The medical insurance payment standard is RMB 5.39 per tablet, which is equivalent to RMB 10.78 per day for taking medication twice a day according to approval, making it one of the most favorable prices for oral anti-diabetic drugs in medical insurance payment standards so far. The company has reached several milestones related to the development of doglitin in 2023 and received a non-refundable milestone payment of RMB 800 million. The new version of the national medical insurance drug catalogue was implemented on January 1 of this year. The company expects multiple
HUA MEDICINE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Hualing Pharmaceutical-B (02552.HK) held a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 18 | Hualing Pharmaceutical-B (02552.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve, including the Group's annual results for the year ended December 31, 2023, and the proposed final dividend (if any), and other matters.
HUA MEDICINE-B: Date of Board Meeting
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Changes in Hong Kong stocks | Hualing Pharmaceutical-B (02552) rose more than 6%. Second-generation GKA submitted an IND application to the US FDA, Huatangning's sales volume can be expected
Hualing Pharmaceutical-B (02552) rose more than 6%. As of press release, it rose 6.19% to HK$2.4, with a turnover of HK$6.734,900.
Home Linjiang: Hong Kong stocks in 2024, or the continuation of the structured market...
The Hang Seng Healthcare Index has generally produced good companies over the past few years, and they deserve a lot of attention from investors in 2024.
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US
Hua Medicine (HKG:2552) has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for permission to conduct trials of the firm's second generation anti-dia
China Includes Hua Medicine's Type 2 Diabetes Medication in Drug Reimbursement List
China's medical products administrator included Hua Medicine's (HKG:2552) HuaTangNing glucokinase allosteric activator under the country's national reimbursement drug list effective Jan. 1, 2024, a We
Changes in Hong Kong stocks | Pharmaceutical stocks rebounded strongly, innovative drugs accelerated access to health insurance, and global biomedical investment and financing data recovered slightly
The health insurance negotiation policy continues to favor innovative drugs, and the success rate of innovative drug negotiations has reached 92%. Furthermore, as the Fed's interest rate hike cycle nears its end, global biomedical investment and financing data for the third quarter recovered slightly.
No Data